BioStem Technologies, Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced today that it will release its first quarter 2026 financial results on Thursday, May 14, 2026. The company will host a conference call and webcast at 4:30 PM ET to discuss the results and provide an overview of the quarter from management.
The announcement comes as BioStem continues to expand its portfolio of allograft solutions, which are used by clinicians across a wide range of specialties. The company's proprietary processing technologies—BioRetain, CryoTek, and SteriTek—are designed to preserve the natural properties of perinatal tissues, supporting their clinical use. BioStem's quality management system is accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and current Good Manufacturing Processes.
Investors and interested parties can register for the webcast by clicking here. The conference call can be accessed via North America toll-free at (800) 715-9871 or internationally at +1 (646) 307-1963, using conference ID 9695874.
The financial results release is a key event for shareholders and industry observers, as it will provide insight into the company's performance during the first quarter. BioStem has been focused on advancing innovation in regenerative medicine, with a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint. The company's product lines include Neox, Clarix, VENDAJE, and American Amnion.
BioStem's latest news and updates are available in the company's newsroom at https://tinyurl.com/bsemnewsroom. The company also encourages followers to join its email distribution list and follow it on social media platforms like X and LinkedIn for real-time updates.
The conference call and webcast will be crucial for analysts and investors looking to gauge the company's financial health and strategic direction. BioStem's focus on regenerative medicine places it at the forefront of a rapidly evolving field, and its quarterly results could signal broader trends in the industry. The company's ability to leverage its proprietary technologies and maintain regulatory compliance will be key factors in its continued growth.
For more information, visit BioStem's website at www.biostemtechnologies.com.
